Arcus Biosciences (RCUS) announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by the FDA for the treatment of pancreatic cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences treatment of pancreatic cancer granted orphan designation
- Arcus Biosciences Advances Phase 1 Study for Promising Cancer Treatment
- Gilead and Arcus Biosciences’ Promising Oncology Study Update
- Arcus Biosciences’ AB598 Study: A New Frontier in Cancer Treatment
- Gilead and Arcus Advance Promising Colorectal Cancer Study